Varenicline
- Generic Name
- Varenicline
- Brand Names
- Champix, Chantix, Tyrvaya
- Drug Type
- Small Molecule
- Chemical Formula
- C13H13N3
- CAS Number
- 249296-44-4
- Unique Ingredient Identifier
- W6HS99O8ZO
- Background
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors.
On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced.
- Indication
For use as an aid in smoking cessation.
Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- Smoking, Cessation
Sympathovagal Balance in Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2017-10-25
- Target Recruit Count
- 85
- Registration Number
- NCT01474265
- Locations
- 🇩🇪
University Medical Center, Goettingen, Germany
Pilot Study of Varenicline to Treat Opioid Dependence
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 21
- Registration Number
- NCT01436474
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Varenicline In-Patient Study
- Conditions
- Interventions
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 17
- Registration Number
- NCT01413516
- Locations
- 🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States
Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Duke University
- Target Recruit Count
- 282
- Registration Number
- NCT01406223
- Locations
- 🇺🇸
Duke Center for Nicotine and Smoking Cessation Research, Raleigh, North Carolina, United States
Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: (DIASMOKE)
- Conditions
- Interventions
- First Posted Date
- 2011-07-04
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- Universita degli Studi di Catania
- Target Recruit Count
- 300
- Registration Number
- NCT01387425
- Locations
- 🇮🇹
Centro per la Prevenzione e Cura del Tabagimso, Catania, Italy
🇮🇹Centro per la Prevenzione eCura del Tabagimso, Catania, Italy
Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients
- Conditions
- Interventions
- First Posted Date
- 2011-06-23
- Last Posted Date
- 2021-03-11
- Lead Sponsor
- Albert Einstein College of Medicine
- Target Recruit Count
- 100
- Registration Number
- NCT01378858
- Locations
- 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
Varenicline for Methamphetamine Dependence
- Conditions
- Interventions
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 52
- Registration Number
- NCT01365819
- Locations
- 🇺🇸
UCLA Vine Street Clinic, Los Angeles, California, United States
Varenicline Treatment for Active Alcoholic Smokers
- Conditions
- Interventions
- First Posted Date
- 2011-05-04
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 33
- Registration Number
- NCT01347112
- Locations
- 🇺🇸
Franciscan Skemp Hospital, La Crosse, Wisconsin, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Varenicline for Gait and Balance Impairment in Parkinson Disease
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT01341080
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
Extended Treatment for Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 223
- Registration Number
- NCT01330043
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.